How the Availability of Capital Impacts the Role of the CMO

At the May 2015 Chief Medical Officer’s Summit in Boston, we featured a session on:
How the Availability of Capital Impacts the Role of the CMO
In this session, the panelists cover:

Optimal use of the proceeds
Determining a development path, new molecules vs. new studies on the same molecules
Appropriate stewardship of the capital
Balancing short-term and long-term objectives; particularly when they may conflict
Concerns and/or benefits of early financing without having reached clinical goals
Examining the new threshold in moving development forward
How is the progress in the industry translating into new drug discovery?
Maintaining the same rigor for investment

Moderated by: Louis Brenner, MD Chief Operating Officer, Allena Pharmaceuticals
Panelists: Raj Malik, MD CMO, G1 Therapeutics
Jim Roach, MD CMO and SVP, Development, Momenta Pharmaceuticals
Oliver Rosen, MD CMO, Deciphera Pharmaceuticals
Ian Walters, MD VP and CMO, Intensity Therapeutics

The next CMO Summit is November 9-10 in Burlingame, California. It is one of the best face-to-face opportunities for R&D leaders in emerging biotechs to:
1. Address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits.

2. To create a network of CMOs & other R&D leaders from small to midsize life science companies to share ideas, solutions and support.

For information, visit www.theconferenceforum.org

Partial and full scholarships available for start-ups.